Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography Authors: Nikola Lübbering, Alexander Krogmann, Felix Jansen, Eicke Latz, Georg Nickenig, Sebastian Zimmer, Marc W. Merx, Marc W. Merx, Marc W. Merx Published: 2025 ABSTRACT BackgroundAtherosclerosis is a chronic inflammatory disease driven by endothelial dysfunction, cholesterol accumulation, and immune activation leading to thrombosis and vascular stenosis. While LDL-lowering therapies are firmly established, targeting the underlying inflammation is still an emerging strategy. Cholesterol crystals (CC) contribute to inflammation by activating the NLRP3 inflammasome in monocytes and promoting disease progression. Cyclodextrin (CD), an FDA-approved drug carrier, has shown atheroprotective effects by enhancing cholesterol metabolism and reducing inflammation in preclinical models. This study investigated whether CC-uptake in human monocytes, a prerequisite for inflammasome activation, is also influenced by CD pretreatment.MethodsHuman peripheral mononuclear cells were isolated from whole blood samples provided by 76 patients undergoing coronary angiography at the University Hospital Bonn between November 2017 and February 2018. After separation, peripheral mononuclear cells were stimulated with 2-Hydroxypropyl-γ-Cyclodextrin and CC. CC-uptake by monocytes was analyzed using flow cytometry.ResultsCC-uptake by monocytes varied greatly between patients (8–37%), with lower uptake observed in patients with elevated leukocytes (p = 0.0058) and diabetes mellitus (p = 0.0448). CD-pretreatment significantly reduced CC-uptake (20.1% ± 0.8% vs. 15.0% ± 0.6%, p < 0.0001). Interindividual variability in CD response (CCΔCD) was noted; 40 patients exhibited a significant reduction in CC-uptake, while nine showed an increase. Patients with coronary artery disease (CAD) (p = 0.0316), requirement for percutaneous coronary intervention (PCI) (p = 0.0030), and elevated leucocyte levels (p = 0.0135) had lower CCΔCD, suggesting a link between systemic inflammation and attenuated CD efficacy.ConclusionWe demonstrated that CD significantly reduced CC-uptake in patients undergoing coronary angiography, which supports its role in inhibiting CC-phagocytosis and promoting cholesterol efflux. Interestingly, patient response to CD varied, with those exhibiting greater systemic inflammation or CAD showing a less pronounced reduction in CC-uptake. Our findings provide insight into the atheroprotective mechanisms of CD and suggest its potential utility in evaluating individual cardiovascular risk and monitoring CD-based therapeutic interventions in humans. Introduction Atherosclerosis is a chronic inflammatory disease of the arterial wall. According to current disease models, classic cardiovascular risk factors damage the endothelium and impair its function. This promotes the accumulation of cholesterol in the subendothelial space, triggering chronic inflammation and leading to thrombosis and stenosis of arterial vessels, which can cause heart attacks, strokes, and peripheral vascular disease [1,2]. Collectively, these conditions represent the leading cause of death worldwide [3], underscoring the urgent need for novel therapeutic approaches to reduce disease risk. While current treatments primarily focus on reducing low-density lipoprotein (LDL) cholesterol, not all patients achieve adequate LDL reduction [4–6]. Recent studies are targeting the underlying chronic inflammation as a promising pharmaceutical strategy [7–9]. Excessive cholesterol accumulation in atherosclerotic lesions results in the formation of cholesterol crystals (CCs) deposited in the subendothelial extracellular space. The phagocytosis of CCs by invading monocytes causes lysosomal damage, which activates an inflammatory response via the NLRP3 inflammasome [10,11]. Thus, reducing CC-phagocytosis may help mitigate systemic inflammation and slow the progression of atherosclerotic lesions. Human peripheral blood mononuclear cells (PBMCs), comprising lymphocytes and monocytes, are key indicators of inflammation. Both lymphocytes and monocytes play significant roles in atherosclerosis pathogenesis, with monocytes—particularly those that differentiate into macrophages—predominating in atherosclerotic lesions. Monocytes are a heterogeneous population, classified into three main subsets: classical (CD14++CD16−), intermediate (CD14++CD16+), and non-classical (CD14 + CD16++). Classical and intermediate subsets have been shown to predict cardiovascular event rates, while Hamers et al. revealed heterogeneity within the non-classical subset. Certain subpopulations in this group are more frequent in severe coronary artery disease (CAD), suggesting potential therapeutic targets [12–15]. In general, macrophages are programmed to contribute to the progression of advanced atherosclerotic lesions through excessive cholesterol uptake. Impaired cholesterol efflux further exacerbates cholesterol accumulation, creating a pro-inflammatory and pro-atherosclerotic environment [10,16–19]. Previous studies have demonstrated that cyclodextrin (CD), an FDA-approved compound used for delivering lipophilic drugs [20], has beneficial effects on atherogenesis. CD promotes macrophage reprogramming toward a more efficient cholesterol metabolism and an anti-inflammatory phenotype [21,22]. We now tested whether 2-Hydroxypropyl-γ-CD-pretreatment of human monocytes impacts CC-uptake and thereby affects the innate inflammatory stimulus. Materials and methods CC-preparation For CC-preparation, 20 mg cholesterol was dissolved in 10 ml 1-propanol and subsequently incubated in 15 ml distilled water at room temperature for 10 min. A CC-pellet was produced by centrifugation at 3400 rpm for 10 min and dried in a vacuum centrifuge at 30 °C for 8–12 hours. Afterwards, CC were resuspended in 1 ml 0.1% fetal-bovine serum in phosphate-buffered saline (PBS) and finally treated in an ultrasonic bath for 10 min. Flow cytometry was used to determine the exact number of CC-particles. Sampling and stimulation Whole blood samples were collected from 76 patients undergoing coronary angiography between 15/11/2017 and 14/02/2018. This study was approved by the University Bonn Ethics Committee on 25/06/2014. All participants provided written informed consent prior to enrolment in the study. For separation of PBMC, a cell separation medium with a polyester gel and a density gradient liquid was used [23]. PBMC were dissolved in the patient`s own serum (7.2 ml) and diluted in (7.8 ml) PBS. The PBMC were preincubated with 2-Hydroxypropyl-γ-CD (10 mM) or PBS control for 6h at 37°C and subsequently incubated with CC (120 x 106 particles) for 30 min at 37°C. The concentration of 10mM CD was selected based on our own previously published data demonstrating adequate biological activity without cytotoxic effects at this dose [22]. CC-uptake by monocytes was evaluated and quantified by flow cytometry. To increase validity of the result, samples were stimulated and measured in triplets (S1 and S2 Figs). Cell count by flow cytometry resulted in approximately 100,000 cells per sample. After stimulation with CD and CC, PBMC were treated with 12.5µl 4% paraformaldehyde in PBS. To differentiate monocytes from lymphocytes and cell debris, we used three different monoclonal antibodies: PE anti-human CD11b (Clone ICRF44, BioLegend, San Diego, CA, USA), FITC anti-human CD14 (Clone M5E2, BioLegend) und PerCP anti-human CD45 (Clone 2D1, BioLegend) (Dilution: 1 µg/test). We analyzed 10,000 cells per sample in a predefined PBMC-gate. Gating strategy CD45 + Monocytes and lymphocytes were separated from CD45- cell debris. A “single-cell”-gate was used to remove duplets from further analysis [24]. Monocytes were separated from lymphocytes as CD14+/CD11b+-cells. CC-uptake was defined and quantified by a shift in side scatter, which reflects increased granularity after phagocytosis, as previously described by Samstad et al. [25]. For each patient, we acquired an unstimulated control sample (PBMC without CC-stimulation) to define the side scatter characteristics of monocytes in the absence of crystals. On this control, an individual, cell-free side scatter gate was placed directly above the population of monocytes. Monocytes incubated with CC showed a shift in side scatter into this predefined gate. The proportion of monocytes in this gate was further analyzed (Fig 1). Gating strategy. 1.) CD45+ positive cells were selected. 2.) Single cells were identified and duplets excluded. 3.) CD14+/CD11b+ monocytes (upper right) were gated. 4.) A gate with higher SSC-A was selected using CD14+/CD11b+ monocytes without CC-incubation. 5.) SSC-A-Shift is observed upon CC-uptake by CD14+/CD11b+ monocytes. (CD 11b, 14, 45: Cluster of Differentiation, CC: Cholesterol Crystals). Statistics Categorical variables were analyzed using Chi-squared tests. Post-hoc analyses were performed by Fisher`s exact test, and the data are presented as absolute numbers and percentages. Normality of continuous variables was assessed by Q-Q plots and the Shapiro-Wilk test. For normally distributed continuous variables, unpaired Student`s t-tests or ANOVA (for multiple comparisons) were used. Post-hoc comparisons were performed with the Sidak`s test. Data are presented as mean ± standard error of mean (s.e.m.). For non-normally distributed variables (Shapiro-Wilk p < 0.05), group comparisons were performed using the Mann-Whitney U test, and the data are presented as median [interquartile range, IQR]. p < 0.05 was considered statistically significant. Analyses were performed with Excel (Microsoft), Prism (GraphPad Software Inc.) and SPSS (IBM). Results Whole blood samples were collected from 76 patients via the side port of an arterial sheath prior to coronary angiography. The average age of the patients included in our study was 71 years and 70% were male. Most were elective procedures (72%). CAD was diagnosed in two thirds of patients (66%) and 29% required percutaneous coronary intervention (PCI). The mean left ventricular ejection fraction (EF) was 55.5%. As previously described, CC-uptake results in an increase in granularity, which was defined as an increase in side scatter. As proof of concept, monocytes that were not previously incubated with CC did not show a change in side scatter (p < 0.0001) (Fig 2A). The relative number of monocytes that incorporated CC ranged between 8 and 37%. To evaluate whether specific patients` characteristics were associated with these interindividual differences, we divided the collective into two groups based on the median of the gaussian distribution of the CC-uptake (20%) (Fig 2B). Patients with elevated plasma levels of leukocytes (p = 0.0058) or diabetes mellitus (p = 0.0448) had a significant lower CC-uptake (Table 1 and S1 Table). 10.1371/journal.pone.0338635.t001Table 1Characteristics of patients in relation to CC-uptake.Total collectiveCC-uptake > 20%CC-uptake < 20%p-valueN = 76N = 38N = 38Age Mean – yr71.0 ± 10.672.1 ± 10.569.6 ± 10.90.3126 ≥ 65 yr – no. (%)54 (71)28 (74)26 (68)0.4004Male sex – no. (%)53 (70)27 (71)26 (68)0.5000Structural Parameters EF (%) – median [IQR]59.5 [50.0–65.0]55.0 [49.0–65.0]60.0 [55.0–62.0]0.5171 AS16 (21)9 (24)7 (18)0.3446Reason for Coronary Angiography – no. (%) ACS14 (18)5 (13)9 (24)0.1877 Stable AP7 (9)4 (11)3 (8)0.5000 Elective55 (72)29 (76)26 (68)0.3043Coronary Parameters – no. (%) CAD50 (66)27 (71)23 (61)0.2343 1-vessel9 (12)5 (13)4 (11)0.5000 2-vessel11 (14)5 (15)6 (16)0.5000 3-vessel30 (39)17 (45)13 (34)0.2409 PCI29 (28)14 (37)15 (39)0.5000CVRF – no. (%) Hypertension67 (88)36 (95)31 (82)0.0763 Diabetes mellitus26 (34)9 (24)17 (45) 0.0448 Dyslipidemia50 (66)28 (74)22 (58)0.1132 Active Smoker23 (30)10 (26)13 (34)0.3090Lab Results – median [IQR] LDL (mg/dl)103.0 [80.0–130.8]84.0 [79.5–112.0]118.0 [82.0–152.0]0.0503 CRP (mg/dl)2.3 [1.0–10.6]1.8 [0.7–7.7]3.4 [1.1–13.0]0.1134 Leucocytes (G/l)7.4 [5.8–8.6]6.0 [5.2–7.9]7.9 [6.5–10.7] 0.0058 Patients with lower CC-uptake < 20% show significantly higher leucocyte counts (p = 0.0058) and more often have diabetes mellitus (p = 0.0448). (ACS: Acute Coronary Syndrome, AP: Angina pectoris, AS: Aortic Valve Stenosis, CAD: Coronary Artery Disease, CC: Cholesterol Crystals, CRP: C-reactive Protein, CVRF: Cardiovascular Risk Factors, EF: Ejection Fraction, LDL: Low-Density Lipoprotein, PCI: Percutaneous Coronary Intervention) Characteristics of patients in relation to CC-uptake. Patients with lower CC-uptake < 20% show significantly higher leucocyte counts (p = 0.0058) and more often have diabetes mellitus (p = 0.0448). (ACS: Acute Coronary Syndrome, AP: Angina pectoris, AS: Aortic Valve Stenosis, CAD: Coronary Artery Disease, CC: Cholesterol Crystals, CRP: C-reactive Protein, CVRF: Cardiovascular Risk Factors, EF: Ejection Fraction, LDL: Low-Density Lipoprotein, PCI: Percutaneous Coronary Intervention) CC-uptake after CC-incubation. A) Monocytes showed a significantly higher CC-uptake after CC-incubation than after incubation with PBS-control (p < 0.0001). B) Gaussian distribution of CC-uptake to divide the total collective into two groups (low and high CC-uptake) according to the median at 20%. (CC: Cholesterol Crystals, PBS: Phosphate-buffered saline). We next examined if the CC-uptake of monocytes is affected by pretreatment with CD. The CCΔCD was defined as the difference between CC-uptake of monocytes incubated with PBS control and CC-uptake of monocytes that were previously stimulated with CD. A higher CCΔCD consequently shows a lower CC-uptake after CD-incubation. CD-pretreatment significantly reduced CC-uptake overall (PBS + 40 μl CC in PBS: 20.1% ± 0.8% vs. 10 mM CD + 40 μl CC in PBS: 15.0% ± 0.6%, p < 0.0001). As proof of concept, PBMC that were not incubated with CCs did not show an increase in granularity after CD-stimulation (Fig 3A). CC-uptake after CD-stimulation. A) CD-pretreatment significantly reduced CC-uptake overall (PBS + 40 µl CC in PBS: 20.1% ± 0.8% vs. 10mM CD + 40 µl CC in PBS: 15.0% ± 0.6%, P < 0.0001). PBMC that were not incubated with CC did not show an increase in granularity after CD-stimulation. B) Gaussian distribution of CCΔCD to divide the total collective into two groups (low and high CCΔCD) according to the median at 5.6%. (CC: Cholesterol Crystals, CD: Cyclodextrin, PBMC: Peripheral Mononuclear Cells, PBS: Phosphat-buffered Saline). The CCΔCD showed interindividual variance. PBMC derived from 40 patients demonstrated an individually significant CCΔCD, whereas cells from nine patients exhibited an increase in CC-uptake following CD-stimulation. To understand these interindividual differences in PBMC phenotype, we compared patients` characteristics according to their CCΔCD. Patients were divided into two groups based on the median of the gaussian distribution of the CCΔCD (5.6%) (Fig 3B). Significantly more patients with CAD (p = 0.0316), PCI (p = 0.0030) or elevated plasma levels of leucocytes (p = 0.0135) showed an attenuated CCΔCD (< 5.6%), indicating that the CCΔCD could potentially function as an indicator for higher inflammation, CAD or the requirement for PCI (Table 2). Within the subgroup of patients with CAD, individuals with three-vessel disease were significantly more frequent in the attenuated CCΔCD group (p = 0.0216), whereas one- and two-vessel disease were not overrepresented, suggesting that a higher plaque burden may be associated with a reduced CCΔCD (Table 2 and S2 Table). 10.1371/journal.pone.0338635.t002Table 2Characteristics of patients in relation to CCΔCD.Total collectiveCCΔCD > 5.6%CCΔCD < 5.6%p-valueN = 76N = 40N = 36AgeMean – yr71.0 ± 10.670.9 ± 10.570.1 ± 11.20.9342≥ 65 yr – no. (%)54 (71)27 (68)27 (75)0.3212Male sex – no. (%)53 (70)29 (73)24 (67)0.3807Structural ParametersEF (%) – median [IQR]59.5 [50.0–65.0]60.0 [50.8–65.0]56.5 [42.5–60.0]0.1556AS16 (21)12 (26)4 (13)0.1478Reason for Coronary Angiography – no. (%)ACS14 (18)7 (18)7 (19)0.5296Stable AP7 (9)3 (8)4 (11)0.4402Elective55 (72)30 (75)25 (69)0.3878Coronary Parameters – no. (%)CAD50 (66)22 (55)28 (78) 0.0316 1-vessel9 (12)6 (15)3 (8)0.29622-vessel11 (14)5 (13)6 (17)0.42393-vessel30 (39)11 (28)19 (53) 0.0216 PCI29 (28)9 (23)20 (56) 0.0030 CVRF – no. (%)Hypertension67 (88)37 (93)30 (83)0.1899Diabetes mellitus26 (34)13 (33)13 (36)0.4640Dyslipidemia50 (66)24 (60)26 (72)0.1898Smoker23 (30)11 (28)12 (33)0.3807Lab Results – median [IQR]LDL (mg/dl)103.0 [80.0–130.8]107.0 [80.0–137.3]93.0 [79.3–121.0]0.3052CRP (mg/dl)2.3 [1.0–10.6]1.8 [1.1–9.9]3.6 [1.0–12.8]0.4814Leucocytes (G/l)7.4 [5.8–8.6]6.4 [5.3–8.2]7.8 [6.1–10.6] 0.0135 Patients without a significant CCΔCD have significantly more often CAD (p = 0.0316), need PCI (p = 0.0030) and show high plasma levels of leucocytes (p = 0.0135). (ACS: Acute Coronary Syndrome, AP: Angina pectoris, AS: Aortic Valve Stenosis, CAD: Coronary Artery Disease, CC: Cholesterol Crystals, CRP: C-reactive Protein, CVRF: Cardiovascular Risk Factors, EF: Ejection Fraction, LDL: Low Density Lipoprotein, PCI: Percutaneous Coronary Intervention) Characteristics of patients in relation to CCΔCD. Patients without a significant CCΔCD have significantly more often CAD (p = 0.0316), need PCI (p = 0.0030) and show high plasma levels of leucocytes (p = 0.0135). (ACS: Acute Coronary Syndrome, AP: Angina pectoris, AS: Aortic Valve Stenosis, CAD: Coronary Artery Disease, CC: Cholesterol Crystals, CRP: C-reactive Protein, CVRF: Cardiovascular Risk Factors, EF: Ejection Fraction, LDL: Low Density Lipoprotein, PCI: Percutaneous Coronary Intervention) To further analyze the CCΔCD, we compared the collective according to the requirement for PCI. Patients requiring PCI showed a significantly attenuated CCΔCD (p = 0.0004) (Fig 4). CCΔCD and the requirement for PCI. A) Patients are divided into two groups – low and high CCΔCD. In each group, CC-uptake before and after CD-stimulation is visualized. Numbers of patients requiring PCI are significantly higher in the CCΔCD-group. B) CCΔCD showed great interindividual variance. Patients who required PCI showed a significantly attenuated CCΔCD (p = 0.0004). (CC: Cholesterol Crystals, CD: Cyclodextrin, PCI: Percutaneous Coronary Intervention). Discussion In this study, we tested the hypothesis that CD affects CC-phagocytosis by circulating monocytes. Pretreatment of human monocytes with CD significantly reduced CC-uptake in patients undergoing coronary angiography. A potential mechanism underlying this reduction is decreased complement activation and reduced expression of complement receptors on the monocyte surface, leading to diminished CC-phagocytosis [21]. Additionally, our own previously published work has shown that CD increases CC-solubility and promotes the formation of oxysterols, which activate liver-X-receptor (LXR) signaling and induce an atheroprotective transcriptional program in macrophages [22]. Atheroprotective effects of CD have been shown to be LXR-dependent, as CD upregulates LXR target genes, such as ABCA1 and ABCG1, to stimulate reverse cholesterol transport. Furthermore, cholesterol efflux has been observed even in ABCA1- and ABCG1-deficient mice, suggesting the involvement of alternative pathways to reduce CC-burden in monocytes and macrophages [22,26–29]. Beyond metabolic effects, LXRs exhibit anti-inflammatory properties, as their activation suppresses NF-κB and NLRP3, reducing IL-1β production [17,22,26,28,30–32]. As CC-phagocytosis activates the NLRP3 inflammasome and triggers IL-1β release, reducing CC-uptake in circulating monocytes may have significant anti-inflammatory potential [11,33]. Although CD reduced CC-uptake overall, the magnitude of reduction (CCΔCD) varied considerably among patients. We explored why some patients exhibited a pronounced reduction in CC-uptake after CD stimulation, while others showed little to no effect. Analysis of medical characteristics revealed that patients with negligible CCΔCD more frequently had CAD, required coronary intervention, and displayed higher plasma leukocyte levels. These findings suggest that patients with greater systemic inflammation, indicated by elevated leukocytes, or with a higher CAD burden, respond differently to CD treatment ex vivo. While both acute and chronic inflammation are known to activate the complement system, it remains unclear whether complement suppression by CD directly contributes to the observed reduction in CC-uptake. Previous studies have indicated that chemical modifications of CD influence its ability to reduce CC-uptake by monocytes. For instance, α-CD has shown similar effects, but 2-Hydroxypropyl-β-CD failed to reduce CC-uptake in a separate trial [21,34]. Notably, CD pretreatment duration varied between studies, with longer incubation times yielding stronger effects. In the present study, PBMC were preincubated with CD for six hours before CC-stimulation to allow sufficient interaction with monocytes. On the basis of our group`s previously published work on CD-induced LXR activation, it is plausible that prolonged exposure facilitates intracellular action of CD and could enable LXR-dependent gene regulation; however, intracellular CD-uptake and transcriptional responses were not directly assessed here and therefore remain speculative [22]. Interestingly, baseline CC-uptake by monocytes also varied among patients. Those with lower CC-uptake exhibited significantly higher plasma leukocyte levels and were more likely to have diabetes mellitus, suggesting that subliminal systemic inflammation may reduce CC-uptake. This finding contrasts with data from Pilely et al., who demonstrated increased CC-phagocytosis in the presence of acute-phase proteins and complement activation [35]. To assess whether the observed differences in CC-uptake could be explained by treatment rather than by patient characteristics, we analyzed concomitant cardiovascular and metabolic medications (S3 and S4 Tables). The use of antiplatelet therapy, oral anticoagulation, statins and guideline-directed antihypertensive therapy was comparable between patients with low and high CC-uptake, arguing against a major medication-related confounder of the baseline CC-uptake. CD may represent a potential candidate for further investigation as a therapeutic approach in atherosclerosis, with documented benefits including reduced atherosclerotic lesion size, decreased CC-burden, plaque regression, enhanced reverse cholesterol transport, and reduced systemic inflammation [21,22]. While reducing CC-phagocytosis represents one aspect of CD’s potential, a comprehensive understanding of its anti-inflammatory properties necessitates further investigation. Specifically, genetic analysis of monocytes following CD stimulation is essential to assess potential LXR induction, increased expression of abca1 and -g1, and decreased nlrp3 expression, which could result in reduced cytokine secretion. Limitations This study has several limitations. First, the time between blood collection and sample processing ranged from 15 minutes to 3 hours, potentially affecting cell stability. Second, plasma monocyte levels varied between patients, yet a fixed number of PBMCs was used for each experiment. Third, only a single CD concentration (10 mM) was tested; it remains unclear whether different concentrations might yield distinct effects. Furthermore, we did not include a dedicated live/dead staining in the flow-cytometric assay; although 10mM CD has been shown to be subtoxic in our previous work [22], an influence of non-viable cells on side-scatter-based quantification of CC-uptake cannot be fully excluded. In addition, information on concomitant cardiovascular and metabolic medication was obtained from clinical charts and not dose-standardized, so minor medication-related confounding cannot be fully excluded. In 71 of 76 patients, blood collection was performed before the administration of ASA (Acetylsalicylic acid) and/or heparin. The remaining 5 patients presented with non-ST-elevation myocardial infarction and received ASA and heparin prior to blood collection. An ASA/Heparin-related confounder therefore cannot be completely ruled out; however, given the small number of affected cased, a relevant bias appears unlikely. Our ex vivo assay specifically assessed phagocytosis of cholesterol crystals by circulating monocytes. We did not investigate uptake or signaling in response to vascular calcium deposits. This is a limitation with regard to the full spectrum of coronary atherosclerotic plaque morphology. However, experimental work has shown that crystalline cholesterol is a potent trigger of monocyte and macrophage activation and NLRP3 inflammasome signaling, whereas monocytes do not phagocytose macro calcified plaque components to a comparable extent [11]. Our focus in this study was therefore on cholesterol crystals as the biologically relevant particulate stimulus for circulating monocytes. Conclusion Our study examined the effect of CD on CC-phagocytosis by monocytes, revealing CD significantly reduces CC-uptake. Interestingly, patient responses to CD varied, with those exhibiting greater systemic inflammation or coronary artery disease showing a less pronounced reduction in CC-uptake. Our finding provide insight into the atheroprotective mechanisms of CD and suggest its potential utility in evaluating individual cardiovascular risk and monitoring CD-based therapeutic interventions in humans. Supporting information Experimental Setup. PBMC were stimulated with CD and incubated at 37°C for 6 hours. Afterwards they were stimulated with CC at 37°C for another 30 min. CC-uptake was analysed by Flow cytometry. (CC: Cholesterol Crystals, CD: Cyclodextrin, PBMC: Peripheral Mononuclear Cells). (PDF) Stimulation. 12 samples per patient – 6 stimulated with CD and 6 incubated with PBS-control. In each group triplets stimulated with CC and 3 samples incubated with PBS-control. (CD: Cyclodextrin, PBMC: Peripheral Mononuclear Cells, PBS: Phophat Buffered Saline). (PDF) Cholesterol levels in patients in relation to CC-uptake. Patients with higher CC-uptake tended to have lower LDL, although this did not reach statistical significance. No differences in HDL or total cholesterol were observed in relation to CC-uptake. Data are presented as median (IQR) and groups were compared using the Mann–Whitney U test. (CC: Cholesterol Crystals, LDL: Low-Density Lipoprotein, HDL: High-Density Lipoprotein). (PDF) Cholesterol levels in patients in relation to CCΔCD. No differences in LDL, HDL or total cholesterol were observed across CCΔCD groups. Data are presented as median (IQR) and groups were compared using the Mann–Whitney U test. (CC: Cholesterol Crystals, LDL: Low-Density Lipoprotein, HDL: High-Density Lipoprotein). (PDF) Concomitant medication according to CC-uptake. No significant differences in medication were observed between patients with low and high CC-uptake (all p > 0.05). Data are shown as n (%). (CC: Cholesterol Crystals, ASA: Acetylsalicylic Acid, DAPT: Dual Antiplatelet Therapy, VKA: Vitamin K Antagonist, ARB: Angiotensin receptor blocker, PPI: Proton Pump Inhibitor). (PDF) Concomitant medication according to CCΔCD. Medication profiles were comparable across CCΔCD (all p > 0.05). Data are shown as n (%). (ASA: Acetylsalicylic Acid, DAPT: Dual Antiplatelet Therapy, VKA: Vitamin K Antagonist, ARB: Angiotensin receptor blocker, PPI: Proton Pump Inhibitor). (PDF) 29 Oct 2025 PONE-D-25-33939Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography.PLOS ONE Dear Dr. Luebbering, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please be sure to address all the points raised by the expert reviewers and quoted below. Please submit your revised manuscript by Dec 13 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Marc W. Merx, MD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors investigated uptake of cholesterol crystals of human monocytes of patients undergoing coronary angiography and the influence of cyclodextrin treatment. They observed reduction of cholesterol crystal uptake under cyclodextrin treatment with different response depending on individual patients risk factors providing import evidence for cyclodextrin as potential therapeutic strategy in the future to reduce CV events. I recommend to accept the manuscript with major revisions stated below: 1. The authours should provide information on concomitant medication of investigated patients and should discuss potential medication confounders affecting uptake of cholesterol crystals. They also should discuss potential influence of medication used during acute coronary syndrome like aspirin or heaprine. 2. Was a dead-and-alive staining included into the flow cytometry analyisis? If not please comment on this in the discussion section as dead cells included in the analysis might influence SSC shift for cholesterol crystal uptake. Reviewer #2: The authors present an ex-vivo analysis of human PBMC investigating cyclodextrin, an FDA-approved drug carrier, has shown atheroprotective effects by enhancing cholesterol metabolism and reducing inflammation and cholesterol crystals. The authors show that cyclodextrin reduces cholesterol crystals uptake in patients undergoing coronary angiography. They hypothesize that these findings supports the role of cyclodextrin in inhibiting phagocytosis of cholesterol crystals and thus, promoting cholesterol efflux. Further, the authors state that observed ex-vivo effects are due to transcriptional changes While the topic is highly relevant, there are major flaws that limit the quality of the manuscript. Major remarks 1. The authors use circulating monocytes for the experiments. This model is significantly flawed, as resident cells in plaque tissue may have different characteristics. Circulating monocytes are usually not in contact with cholesterol crystals, thus greatly limiting the biological rigor of the finding. 2. Sideward scatter is a very general measure that can indicate a lot of things, e.g., different granules. The authors do not show that the increase in sideward scatter is in fact induced by cholesterol. This must be demonstrated. 3. The authors should provide data on the association of CC uptake and plaque burden and cholesterol levels in patients. 4. Calcified plaques are the most common finding in coronary atherosclerosis – yet, calcium was not assessed here which is a significant limitation towards the real situation. 5. The statistical analysis lacks assessment of normal distribution and appropriate testing of non-normally distributed values 6. Page 8: The sentence “CD-143 incubation of PBMC for six hours before CC-stimulation allows for internalization of CD by monocytes and may lead to transcriptional changes as described above” should also be moved to the Discussion section. Since internalization of CD was not directly validated (only surface markers were assessed via FACS), this causal claim cannot be supported by the current data. Likewise, any mention of transcriptional changes should be either substantiated with transcriptomic evidence or clearly stated as a hypothesis based on previously published findings (with appropriate references). 7. Calculation of CCΔCD introduces another step of calculation that may lead to bias. The authors should argue, based on current literature, why this value was introduced rather than showing normalized or raw data. 8. In several points in the manuscript, the authors refer to gene expression changes, this is not backed up by the data and should be removed. 9. The conclusion “CD has shown potential as a novel therapeutic strategy for atherosclerosis” should be reframed. Given that the current study is based on ex vivo analyses, such a therapeutic claim is not substantiated. A more appropriate phrasing would acknowledge that “CD may represent a potential candidate for further investigation as a therapeutic approach in atherosclerosis.” Minor remarks 1. Please include standard deviations and percentual values where appropriate throughout the manuscript. Additionally, indicate the sample size (n = xy) adjacent to percentage values for transparency. 2. Please rephrase the sentence “The relative number of monocytes that incorporated CC varied individually between 8 and 37%” to “The relative number of monocytes that incorporated CC ranged between 8–37%.” 3. Page 8: The statement “which validates the hypothesis that CD reduces CC-phagocytosis” should be relocated to the Discussion section, as it represents an interpretation rather than a result. 4. The statement “40 patients displayed an individually significant CCΔCD while nine patients developed an increase in CC-uptake after CD-stimulation” requires revision. As the experiments were conducted ex vivo, it would be more accurate to state that “PBMCs derived from 40 patients demonstrated a significant CCΔCD, whereas cells from nine patients exhibited an increase in CC uptake following CD stimulation.” 5. Throughout the manuscript, please replace the term “heart catheterization” with the more precise and clinically appropriate term “coronary angiography.” 6. The sentence “Additionally, CD increases CC solubility and promotes the formation of oxysterols, which activate liver-X-receptor (LXR)” should be either supported by a reference or removed, as there are no LXR-related experiments reported in the current study. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 12 Nov 2025 Dear Reviewers, Thank you for the thorough and constructive assessment of our manuscript. We have revised the text accordingly and respond to each comment point by point below. Where clarifications were requested, we have added them to the Methods, Results, Discussion or Supplementary material. Reviewer 1 1. The authours should provide information on concomitant medication of investigated patients and should discuss potential medication confounders affecting uptake of cholesterol crystals. They also should discuss potential influence of medication used during acute coronary syndrome like aspirin or heaprine. We appreciate this comment, because medication is indeed a potential source of confounding in assays that assess monocyte function ex vivo. We therefore reviewed the medication records of all 76 patients and grouped drugs into clinically meaningful categories (antiplatelet therapy, oral anticoagulation, ACE inhibitor/ARB, β-blocker, calcium-channel blocker, diuretics, statin, antidiabetic therapy, steroids, proton pump inhibitor). We then examined CC uptake and the CC�CD across these medication groups. The results did not show any significant differences across groups and are now provided in Supplementary Tables S3 and S4. We have added a short paragraph to the Discussion to state explicitly that concomitant cardiovascular and metabolic medication was comparable between patients with low and high CC uptake. With regard to acute antithrombotic therapy, we would like to clarify the timing. No STEMI patients were included. Five patients presented with NSTEMI and received aspirin plus intravenous heparin before coronary angiography and before study blood sampling. All remaining 71 of 76 patients were elective cases, and in these patients blood for the study was drawn before periprocedural aspirin and/or heparin were administered. Thus, while we cannot completely rule out an aspirin/heparin-related confounder in the small NSTEMI subset, a systematic medication-induced bias for the overall cohort appears unlikely. We have added this clarification to the Study Limitations. 2. Was a dead-and-alive staining included into the flow cytometry analysis? If not please comment on this in the discussion section as dead cells included in the analysis might influence SSC shift for cholesterol crystal uptake. We appreciate this thoughtful comment. We did not include a separate live/dead staining in the original panel. Our choice of 10 mM cyclodextrin was based on our group’s previously published work (Zimmer et al., 2016), where this CD-concentration was biologically effective but did not show relevant toxicity in macrophages. We have now added a sentence to the Methods to clarify that 10 mM CD was selected because it had been shown to be subtoxic in our previous experiments. In addition, we listed the missing viability staining as a limitation. Reviewer 2 Major remarks 1. The authors use circulating monocytes for the experiments. This model is significantly flawed, as resident cells in plaque tissue may have different characteristics. Circulating monocytes are usually not in contact with cholesterol crystals, thus greatly limiting the biological rigor of the finding. We agree that plaque-resident macrophages and circulating monocytes are not identical and that the plaque microenvironment further shapes macrophage function. In the present study, however, our intention was to interrogate circulating monocytes because several cardiovascular conditions are known to systematically “prime” blood monocytes toward a more proinflammatory or cholesterol-sensitive state (e.g., in coronary artery disease, diabetes or acute coronary syndromes, circulating monocytes show altered subset composition, higher expression of activation markers and enhanced inflammasome responsiveness). In other words, disease-related conditioning already occurs in the blood compartment and can be captured ex vivo. Using PBMC from patients therefore allowed us to study these interindividual, disease-related differences upstream of plaque infiltration and to test whether CD can still reduce CC-induced activation under such conditions. We fully acknowledge that this approach does not reproduce the full complexity of plaque-resident macrophages, but it was chosen deliberately to focus on circulating monocytes as the clinically accessible compartment. 2. Sideward scatter is a very general measure that can indicate a lot of things, e.g., different granules. The authors do not show that the increase in sideward scatter is in fact induced by cholesterol. This must be demonstrated. We apologize for the confusion – we realize that our original description was too brief. We have therefore expanded the gating strategy in “Methods”. As in Samstad et al., 2014, we first acquired a CC-free control from the same patient and placed an individual sideward scatter-gate directly above the monocyte population on this control, i.e. at a level where monocytes without crystals do not appear. After incubation with CC, only monocytes that had taken up CC shifted into this predefined gate, so the sideward scatter-increase reflects CC-dependent phagocytosis. Figure 1 illustrated this gating strategy, and Figure 2A shows monocytes without cholesterol crystal stimulation did not exhibit a shift in sideward scatter. 3. The authors should provide data on the association of CC uptake and plaque burden and cholesterol levels in patients. We appreciate this comment and agree that linking CC-uptake to the extent of coronary artery disease and to circulating lipid levels strengthens the clinical relevance of the assay. In this cohort we used the number of diseased coronary vessels (no CAD, 1-, 2-, 3-vessel CAD) as a pragmatic proxy for plaque burden. CC-uptake and CC�CD were already tabulated across these angiographic categories in the original manuscript (Tables 1 and 2). To make this association more transparent, we have now added a sentence to the Results stating that, among patients with CAD, those with three-vessel disease were significantly more often in the group with an attenuated CC�CD, whereas one- and two-vessel disease were not overrepresented. No association was observed between plaque burden and baseline CC-uptake. In addition, beyond the LDL values that were already reported in the manuscript, we also extracted HDL and total cholesterol and compared these lipid parameters between patients with low versus high CC-uptake and low versus high CC�CD. These results are now provided in Supplementary Tables S1 and S2. In all comparisons, we did not observe significant differences in LDL, HDL, or total cholesterol between the respective CC-uptake or CC�CD groups. 4. Calcified plaques are the most common finding in coronary atherosclerosis – yet, calcium was not assessed here which is a significant limitation towards the real situation. We agree that human coronary atherosclerosis frequently contains calcified components. In the present study we deliberately focused on CC, because circulating monocytes are able to phagocytose CC and mount an NLRP3-dependent inflammatory response, as shown by Duewell et al. 2010., while macrocalcified plaque material is not phagocytosed by monocytes to the same extent. Our assay was designed to model this CC-driven interaction and not the full histological heterogeneity of coronary plaques. We have now added a sentence to the Limitations to clarify that only CC, but not calcium deposits, were assessed in this work. 5. The statistical analysis lacks assessment of normal distribution and appropriate testing of non-normally distributed values. You are right – in the original version we did not explicitly test all continuous variables for normality. We have now repeated the analyses with assessment of normal distribution using Q–Q plots and the Shapiro–Wilk test. Non-normally distributed variables (Ejection fraction, leukocytes, CRP, LDL, HDL, total cholesterol) were re-analyzed using the Mann–Whitney U test, and are now reported as median [IQR]. The corresponding parts in the Methods and Results sections were updated accordingly; these changes did not significantly alter the main conclusion of the study. 6. Page 8: The sentence “CD-143 incubation of PBMC for six hours before CC-stimulation allows for internalization of CD by monocytes and may lead to transcriptional changes as described above” should also be moved to the Discussion section. Since internalization of CD was not directly validated (only surface markers were assessed via FACS), this causal claim cannot be supported by the current data. Likewise, any mention of transcriptional changes should be either substantiated with transcriptomic evidence or clearly stated as a hypothesis based on previously published findings (with appropriate references). Thank you for pointing this out. We have removed the sentence from the Results section and placed a reworded version in the Discussion, where it is treated as an interpretation rather than as a finding. In the revised text we now state that the 6h-preincubation with 10mM CD was chosen to allow sufficient interaction with monocytes and that, based on our group`s previously published work (Zimmer et al., 2016), an LXR-dependent mechanism is plausible. We also explicitly clarify that in the present study we did not directly demonstrate intracellular CD uptake or CD-induced gene expression, and that these mechanisms should therefore be regarded as hypothetical. 7. Calculation of CCΔCD introduces another step of calculation that may lead to bias. The authors should argue, based on current literature, why this value was introduced rather than showing normalized or raw data. Thank you for highlighting this. Our intention with CCΔCD was to capture the within-patient effect of CD despite the very large interindividual variability in baseline CC-uptake. Baseline uptake differed markedly between patients, so expressing the effect of CD as a delta relative to each patient`s own control allows us to compare patients on a common scale and to show how strongly CD modulates CC-uptake in that specific individual. This is why we normalized on an individual-patient basis. At the same time, to ensure transparency, we have kept the untransformed, per-patient measurements in the manuscript: Figure 4A shows the individual raw data points (each dot represents one patient), so readers can see the underlying values in addition to the delta-based summary. 8. In several points in the manuscript, the authors refer to gene expression changes, this is not backed up by the data and should be removed. We have removed the unreferenced sentence in the Discussion and rephrased the remaining parts so that transcriptomic/LXR effects are clearly attributed to previously published work from our group (Zimmer et al. 2016) and are described as plausible mechanisms rather than findings of the present study. 9. The conclusion “CD has shown potential as a novel therapeutic strategy for atherosclerosis” should be reframed. Given that the current study is based on ex vivo analyses, such a therapeutic claim is not substantiated. A more appropriate phrasing would acknowledge that “CD may represent a potential candidate for further investigation as a therapeutic approach in atherosclerosis.” Thank you for this suggestion. We have revised the conclusion exactly as proposed. This wording better reflects the ex vivo character of our study. Minor remarks 1. Please include standard deviations and percentual values where appropriate throughout the manuscript. Additionally, indicate the sample size (n = xy) adjacent to percentage values for transparency. Thank you for your comment. We reviewed the manuscript with this point in mind and confirm that percentages are reported together with their corresponding sample sizes where applicable, and continuous variables are presented with their dispersion measures. 2. Please rephrase the sentence “The relative number of monocytes that incorporated CC varied individually between 8 and 37%” to “The relative number of monocytes that incorporated CC ranged between 8–37%.” We have rephrased the sentence as suggested and now state: “The relative number of monocytes that incorporated CC ranged between 8-37%. 3. Page 8: The statement “which validates the hypothesis that CD reduces CC-phagocytosis” should be relocated to the Discussion section, as it represents an interpretation rather than a result. Thank you for pointing this out. We have removed the sentence from the Results section; the corresponding idea was already addressed in the Discussion. 4. The statement “40 patients displayed an individually significant CCΔCD while nine patients developed an increase in CC-uptake after CD-stimulation” requires revision. As the experiments were conducted ex vivo, it would be more accurate to state that “PBMCs derived from 40 patients demonstrated a significant CCΔCD, whereas cells from nine patients exhibited an increase in CC uptake following CD stimulation.” Thank you for this suggestion. We have rephrased the sentence as suggested to better reflect the ex vivo character of our study. 5. Throughout the manuscript, please replace the term “heart catheterization” with the more precise and clinically appropriate term “coronary angiography.” Thank you for noting this wording issue. We have revised the manuscript and replaced all occurences of “heart catherization” with the clinically more precise term “coronary angiography”. 6. The sentence “Additionally, CD increases CC solubility and promotes the formation of oxysterols, which activate liver-X-receptor (LXR)” should be either supported by a reference or removed, as there are no LXR-related experiments reported in the current study. Thank you for drawing our attention to this. We agree that the statement requires a supporting citation. We have therefore retained the sentence but now explicitly refer to our group`s previously published work (Zimmer et al., 2016), which demonstrated that cyclodextrin solubilizes cholesterol, increases oxysterol availability and activates LXR signaling in macrophages. Submitted filename: Response to Reviewers.docx 25 Nov 2025 Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography. PONE-D-25-33939R1 Dear Dr. Luebbering, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Marc W. Merx, MD Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: no further comments, the authors have addressed all points of concern from the original submission adequately Reviewer #2: The authors have targeted all remarks from Reviewer 1 and me in a point-by-point rebuttal document. Most points were adequately targeted and the manuscript has improved. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** PONE-D-25-33939R1 PLOS One Dear Dr. Lübbering, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Prof. Dr. Marc W. Merx Academic Editor PLOS One